How should we treat tuberculosis in adult patients with chronic kidney disease? Key messages from the British Thoracic Society Guidelines

Polskie Archiwum Medycyny Wewnetrznej

Volumn 120, Issue 10, 2010, Pages 417-422

  Milburn, Heather J ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Chronic kidney disease; Guidelines; Tuberculosis

Indexed keywords

CYCLOSPORIN; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; TACROLIMUS;

CANCER PREVENTION; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; EXTRAPULMONARY TUBERCULOSIS; HEMODIALYSIS; HUMAN; IMMUNE DEFICIENCY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MYCOBACTERIUM TUBERCULOSIS; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TUBERCULIN TEST; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

EID: 78650580503     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.985     Document Type: Review

References (13)

1. Milburn HJ, Ashman N, Davies P, et al.; British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax. 2010;65:557-570.
2. Lightstone L. Preventing renal disease: the ethnic challenge in the United Kingdom. Kidney Int. 2003;63: S135-138.
3. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society. Thorax. 1998;53:7: 536-548.
4. Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Joint Tuberculosis Committee of the British Thoracic Society. Thorax. 2000;55:11: 887-901.
5. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-a treatment. Thorax. 2005;60:800-805.
6. The National Collaborating Centre for Chronic Conditions. Tuberculosis. Clinical diagnosis and management of tuberculosis and measures for its prevention and control March 2006. http://www.nice.org.uk/nicemedia/pdf CG033FullGuideline.pdf. Accessed July 28, 2010.
7. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603-662.
8. Lichtenstein IH, MacGregor RR. Mycobacterial infections in renal transplant recipients: report of five cases and review of the literature. Rev Infect Dis. 1983;5:216-226.
9. CDC and MMWR. Targeted tuberculin testing and treatment of latent tuberculosis infection 9 June 2000/Vol. 49/No. RR-6. http://www.cdc.gov/mmwr/ PDF/rr/rr4906.pdf. Accessed July 28, 2010.
10. Aguado HM, Torre-Cisneros J, Fortun J, et al. Tuberculosis in solid-organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis. 2009;48:1276-1284.
11. Quantrill SJ, Woodhead MA, Bell CE, et al. Pentoneal tuberculosis in patents receiving continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2001;16:1024-1027.
12. Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuberc Lung Dis. 1996;77:37-42.
13. Ann C, Oh KH, Kim K, et al. Effect of pentoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampicin. Perit Dial Int 2003;23:362-367.